Association between use of specialty dietary supplements and c-reactive protein concentrations

American Journal of Epidemiology

Volumn 176, Issue 11, 2012, Pages 1002-1013

  Kantor, Elizabeth D ^a,b   Lampe, Johanna W ^a,b   Vaughan, Thomas L ^a,b   Peters, Ulrike ^a,b   Rehm, Colin D ^b   White, Emily ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

anti inflammatory agents; C reactive protein; chondroitin; dietary supplements; fish oils; glucosamine; inflammation; nutrition surveys

Indexed keywords

C REACTIVE PROTEIN; CHONDROITIN; DIMETHYL SULFONE; FISH OIL; GLUCOSAMINE; HIGH SENSITIVITY C REACTIVE PROTEIN; PYCNOGENOL; UNCLASSIFIED DRUG;

CANCER; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIET; FOOD SUPPLEMENTATION; HEALTH RISK; HEALTH SURVEY; LABORATORY METHOD; MULTIVARIATE ANALYSIS; PROTEIN; PUBLIC HEALTH; SAMPLING;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIET SUPPLEMENTATION; FEMALE; GARLIC; GINKGO BILOBA; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SABAL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CHONDROITIN; CONFIDENCE INTERVALS; DIETARY SUPPLEMENTS; FEMALE; FISH OILS; GLUCOSAMINE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NUTRITION SURVEYS; UNITED STATES;

ALLIUM SATIVUM; GINKGO BILOBA; SERENOA REPENS;

EID: 84870475361     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws186     Document Type: Article

References (92)

1. Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-κB is the lynchpin. Trends Immunol. 2005;26(6): 318-325.
2. Wang S, Liu Z, Wang L, et al. NF-κB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6(5):327-334.
3. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010;2010: 535918. (doi:10.1155/2010/535918).
4. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56(2):69-83.
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
6. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150(6):405-410.
7. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376(9754):1741-1750.
8. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009; 10(5):501-507.
9. Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608-615.
10. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 2005;6(12):945-952.
11. Berger JS, Lala A, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162(1):115.e2-124.e2.
12. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343(8905):1075-1078.
13. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160(6):777-784.
14. Largo R, Alvarez-Soria MA, Díez-Ortego I, et al. Glucosamine inhibits IL-1ß-induced NFKB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003;11(4):290-298.
15. 2 in articular cartilage explants. Osteoarthritis Cartilage. 2005;13(5):387-394.
16. Chan PS, Caron JP, Orth MW. Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J Rheumatol. 2006;33(7):1329-1340.
17. Chou MM, Vergnolle N, McDougall JJ, et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1ß, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood). 2005;230(4):255-262.
18. Sakai S, Sugawara T, Kishi T, et al. Effect of glucosamine and related compounds on the degranulation of mast cells and ear swelling induced by dinitrofluorobenzene in mice. Life Sci. 2010;86(9-10):337-343.
19. 2 and YKL-40. J Rheum Joint Surg. 2002:175-184.
20. Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 2008; 16(suppl 3):S14-S18.
21. Xu CX, Jin H, Chung YS, et al. Chondroitin sulfate extracted from ascidian tunic inhibits phorbol ester-induced expression of inflammatory factors VCAM-1 and COX-2 by blocking NF-KB activation in mouse skin. J Agric Food Chem. 2008;56(20):9667-9675.
22. Kim YH, Kim DH, Lim H, et al. The anti-inflammatory effects of methylsulfonylmethane on lipopolysaccharide-induced inflammatory responses in murine macrophages. Biol Pharm Bull. 2009;32(4):651-656.
23. Lo CJ, Chiu KC, Fu M, et al. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J Surg Res. 1999;82(2):216-221.
24. Zhao Y, Joshi-Barve S, Barve S, et al. Eicosapentaenoic acid prevents LPS-induced TNF-a expression by preventing NFKB activation. J Am CollNutr. 2004;23(1):71-78.
25. Hodge G, Hodge S, Han P. Allium sativum (garlic) suppresses leukocyte inflammatory cytokine production in vitro: potential therapeutic use in the treatment of inflammatory bowel disease. Cytometry. 2002;48(4):209-215.
26. Ide N, Lau BH. Garlic compounds minimize intracellular oxidative stress and inhibit nuclear factor-KB activation. JNutr. 2001;131(3):1020S-1026S.
27. Keiss HP, Dirsch VM, Hartung T, et al. Garlic (Allium sativum L.) modulates cytokine expression in lipopolysaccharide-activated human blood thereby inhibiting NF-KB activity. J Nutr. 2003;133(7):2171-2175.
28. Peralta EA, Murphy LL, Minnis J, et al. American ginseng inhibits induced COX-2 and NFKB activation in breast cancer cells. J Surg Res. 2009;157(2):261-267.
29. 2-terminal kinase and nuclear factor-KB. Mol Endocrinol. 2008;22(1):186-195.
30. Park YM, Won JH, Yun KJ, et al. Preventive effect of ginkgo biloba extract (GBB) on the lipopolysaccharide-induced expressions of inducible nitric oxide synthase and cyclooxygenase-2 via suppression of nuclear factor-κB in RAW 264.7 cells. Biol Pharm Bull. 2006;29(5):985-990.
31. Buck AC. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol. 2004;172(5):1792-1799.
32. Chacón MR, Ceperuelo-Mallafré V, Maymó-Masip E, et al. Grape-seed procyanidins modulate inflammation on human differentiated adipocytes in vitro. Cytokine. 2009;47(2): 137-142.
33. Erlejman AG, Jaggers G, Fraga CG, et al. TNFα-induced NF-κB activation and cell oxidant production are modulated by hexameric procyanidins in Caco-2 cells. Arch Biochem Biophys. 2008;476(2):186-195.
34. Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, et al. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol. 2009;64(3):321-327.
35. Micallef MA, Garg ML. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals. Atherosclerosis. 2009;204(2):476-482.
36. National Center for Health Statistics. NHANES 2003-2004 Public Data General Release File Documentation. Hyattsville, MD: National Center for Health Statistics; 2005. (http://www.cdc.gov/nchs/data/nhanes/nhanes-03-04/general- data-release-doc-03-04.pdf). (Accessed November 11, 2011).
37. Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol. 2000;27(10):2351-2359.
38. National Center for Health Statistics. National Health and Nutrition Examination Survey. 2003-2004 Data Documentation, Codebook, and Frequencies. C-Reactive Protein (CRP), Bone Alkaline Phosphatase (BAP), and Parathyroid Hormone (PTH) (L11-C). Hyattsville, MD: National Center for Health Statistics; 2006. (http://www.cdc. gov/nchs/nhanes/nhanes2003-2004/L11-C.htm). (Accessed November 11, 2011).
39. Ajani UA, Ford ES, Mokdad AH. Dietary fiber and C-reactive protein: findings from National Health and Nutrition Examination Survey data. J Nutr. 2004;134(5): 1181-1185.
40. Aleksandrova K, Jenab M, Boeing H, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol. 2010;172(4):407-418.
41. Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):483-495.
42. Camhi SM, Stefanick ML, Ridker PM, et al. Changes in C-reactive protein from low-fat diet and/or physical activity in men and women with and without metabolic syndrome. Metabolism. 2010;59(1):54-61.
43. Cavicchia PP, Steck SE, Hurley TG, et al. A new dietary inflammatory index predicts interval changes in serum high-sensitivity C-reactive protein. J Nutr. 2009;139(12): 2365-2372.
44. Gao XR, Adhikari CM, Peng LY, et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. J Pharm Pharmacol. 2009;61(11):1505-1510.
45. Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, et al. Ethnic differences in C-reactive protein concentrations. SWAN Investigators. Clin Chem. 2008;54(6):1027-1037.
46. Kent SM, Flaherty PJ, Coyle LC, et al. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J. 2003;145(2):e8. (doi:10.1067/mhj.2003.34).
47. Kraus VB, Stabler TV, Luta G, et al. Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarthritis Cartilage. 2007; 15(8):966-971.
48. Kronish IM, Rieckmann N, Shimbo D, et al. Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. Am J Cardiol. 2010;106(8):1090-1094.
49. Laaksonen DE, Niskanen L, Nyyssönen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004;47(8): 1403-1410.
50. McDade TW, Lindau ST, Wroblewski K. Predictors of C-reactive protein in the National Social Life, Health, and Aging Project. J Gerontol B Psychol Sci Soc Sci. 2011; 66(1):129-136.
51. Plaisance EP, Grandjean PW. Physical activity and high-sensitivity C-reactive protein. Sports Med. 2006;36(5): 443-458.
52. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106(12):1447-1452.
53. Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest. 2007;131(5):1557-1566.
54. Feng D, Tracy RP, Lipinska I, et al. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis. 2000;9(1):37-41.
55. Hovens MM, Snoep JD, Groeneveld Y, et al. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabetes Obes Metab. 2008;10(8):668-674.
56. Kim MA, Kim CJ, Seo JB, et al. The effect of aspirin on C-reactive protein in hypertensive patients. Clin Exp Hypertens. 2011;33(1):47-52.
57. Rogowski O, Shapira I, Ben Assayag E, et al. Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events. Blood Coagul Fibrinolysis. 2006;17(1):19-22.
58. 2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol. 2001;37(8):2036-2041.
59. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5-6):255-258.
60. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878.
61. Gouze JN, Bianchi A, Bécuwe P, et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett. 2002;510(3):166-170.
62. Rafi MM, Yadav PN, Rossi AO. Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of pp38-MAP kinase and transcription factor NF-κB. Mol Nutr Food Res. 2007; 51(5):587-593.
63. Rajapakse N, Kim MM, Mendis E, et al. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-κB signaling. Immunology. 2008;123(3):348-357.
64. Forchhammer L, Thorn M, Met O, et al. Immunobiological effects of glucosamine in vitro. Scand J Immunol. 2003; 58(4):404-411.
65. Hua J, Sakamoto K, Kikukawa T, et al. Evaluation of the suppressive actions of glucosamine on the interleukin-1β-mediated activation of synoviocytes. Inflamm Res. 2007; 56(10):432-438.
66. Shikhman AR, Kuhn K, Alaaeddine N, et al. N-acetylglucosamine prevents IL-1β-mediated activation of human chondrocytes. J Immunol. 2001;166(8): 5155-5160.
67. Nakamura H, Masuko K, Yudoh K, et al. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int. 2007;27(3):213-218.
68. Satia JA, Littman A, Slatore CG, et al. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins And Lifestyle study. Cancer Epidemiol Biomarkers Prev. 2009;18(5): 1419-1428.
69. Brasky TM, Lampe JW, Slatore CG, et al. Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control. 2011;22(9):1333-1342.
70. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.
71. Pocobelli G, Kristal AR, Patterson RE, et al. Total mortality risk in relation to use of less-common dietary supplements. Am J Clin Nutr. 2010;91(6):1791-1800.
72. Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007;99(11):881-889.
73. Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124(7):621-629.
74. Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res. 2007; 55(2):81-95.
75. Freire AC, Basit AW, Choudhary R, et al. Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. Int J Pharm. 2011;415(1-2):15-28.
76. Chapkin RS, Kim W, Lupton JR, et al. Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids. 2009;81(2-3):187-191.
77. Wall R, Ross RP, Fitzgerald GF, et al. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev. 2010;68(5):280-289.
78. Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006; 189(1):19-30.
79. Fritsche K. Fatty acids as modulators of the immune response. Annu Rev Nutr. 2006;26:45-73.
80. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem. 2010;21(9):781-792.
81. Larsson SC, Kumlin M, Ingelman-Sundberg M, et al. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr. 2004;79(6): 935-945.
82. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32(7):365-372.
83. Brasky TM, Lampe JW, Potter JD, et al. Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1696-1708.
84. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA. 2006;295(4):403-415.
85. Saadatian-Elahi M, Norat T, Goudable J, et al. Biomarkers of dietary fatty acid intake and the risk of breast cancer: a meta-analysis. Int J Cancer. 2004;111(4):584-591.
86. Yi SW, Sull JW, Hong JS, et al. Association between ginseng intake and mortality: Kangwha Cohort Study. J Altern Complement Med. 2009;15(8):921-928.
87. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43(1):52-58.
88. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8): 795-808.
89. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the Study on Osteoarthritis Progression Prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(2):524-533.
90. Kowey PR, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010;304(21):2363- 2372.
91. Möller I, Pérez M, Monfort J, et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage. 2010; 18(suppl 1):S32-S40.
92. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010;69(8):1459-1464.